Thank you. Message boards are the wild west of stock discussion and everyone is entitled to their own opinion. I believe we have laid out our investment thesis clearly, using the data to support out investment decision. The fact is, company management has taken to company from concept to commercialization while using limited financial resources. They have done this in a relatively short amount of time. This is characteristic of a strong management team. The company is now pursuing a licensing model which limits cash expenditure and can maximize value in the near term. Royalties from licensing deals create the foundation for continued growth and if proven equally effective in human clinical trials, will likely become a buyout candidate. The amino acid chain that the company has identified and can attach molecules to is present in all mammals and as such similar trial should be present in humans. Those are the facts.

Good investing to you all.